Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2022-11-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-022-00744-z |
| _version_ | 1828309645943373824 |
|---|---|
| author | Rami S. Komrokji Avani M. Singh Najla Al Ali Onyee Chan Eric Padron Kendra Sweet Andrew Kuykendall Jeffrey E. Lancet David A. Sallman |
| author_facet | Rami S. Komrokji Avani M. Singh Najla Al Ali Onyee Chan Eric Padron Kendra Sweet Andrew Kuykendall Jeffrey E. Lancet David A. Sallman |
| author_sort | Rami S. Komrokji |
| collection | DOAJ |
| first_indexed | 2024-04-13T15:31:45Z |
| format | Article |
| id | doaj.art-19be5edb20df4d4c93db17ed5c1bec4e |
| institution | Directory Open Access Journal |
| issn | 2044-5385 |
| language | English |
| last_indexed | 2024-04-13T15:31:45Z |
| publishDate | 2022-11-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj.art-19be5edb20df4d4c93db17ed5c1bec4e2022-12-22T02:41:21ZengNature Publishing GroupBlood Cancer Journal2044-53852022-11-0112111410.1038/s41408-022-00744-zAssessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndromeRami S. Komrokji0Avani M. Singh1Najla Al Ali2Onyee Chan3Eric Padron4Kendra Sweet5Andrew Kuykendall6Jeffrey E. Lancet7David A. Sallman8Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research InstituteDepartment of Hematology/Oncology, University of South Florida & Moffitt Cancer CenterDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center & Research InstituteDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center & Research InstituteDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center & Research InstituteDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center & Research InstituteDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center & Research InstituteDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center & Research InstituteDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institutehttps://doi.org/10.1038/s41408-022-00744-z |
| spellingShingle | Rami S. Komrokji Avani M. Singh Najla Al Ali Onyee Chan Eric Padron Kendra Sweet Andrew Kuykendall Jeffrey E. Lancet David A. Sallman Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome Blood Cancer Journal |
| title | Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome |
| title_full | Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome |
| title_fullStr | Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome |
| title_full_unstemmed | Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome |
| title_short | Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome |
| title_sort | assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome |
| url | https://doi.org/10.1038/s41408-022-00744-z |
| work_keys_str_mv | AT ramiskomrokji assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome AT avanimsingh assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome AT najlaalali assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome AT onyeechan assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome AT ericpadron assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome AT kendrasweet assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome AT andrewkuykendall assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome AT jeffreyelancet assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome AT davidasallman assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome |